A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Cervical Cancer · Gastric/Gastroesophageal Junction Adenocarcinoma · Microsatellite Stable Colorectal Cancer · Non-Small-Cell Lung Cancer · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Renal Cell · Urothelial Carcinoma · Pancreatic Adenocarcinoma · Melanoma · Ovarian Neoplasms · Triple Negative Breast Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 1,109 (planned)
- Started
- May 27, 2021
- Main results expected
- Aug 31, 2031
- Fully finished
- Aug 31, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of adverse events (AEs)
Measured over: Up to 120 weeks
Incidence of serious adverse events (SAEs)
Measured over: Up to 120 weeks
Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria
Measured over: Up to either 21 or 28 days
Incidence of AEs leading to discontinuation
Measured over: Up to 120 weeks
Number of deaths
Measured over: Up to 120 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04895709 · record last updated 2026-08-17 · checked 2026-11-09 15:47 UTC